Roche Holding AG (RHHBY), a pharmaceutical company, announced on Tuesday, that its shareholders approved all proposals presented by the Board of Directors at the company's 2026 Annual General Meeting.
A total of 594 shareholders representing 77.22 percent of the 106,691,000 shares voted to approve the 2025 Annual and Consolidated Financial Statements, as well as the Remuneration and Sustainability reports.
Shareholders also re-elected Severin Schwan as Chairman of the Board with 97.75 percent of the votes and approved a dividend increase to 9.80 Swiss francs per share, marking the company's 39th consecutive dividend increase.
In addition, shareholders re-elected the existing board members and approved the election of Lubomira Rochet to the Board of Directors. They also approved remuneration plans for the board and executive committee and authorized changes to the company's capital structure, including replacing Genussscheine with Participation Certificates listed on the SIX Swiss Exchange.
RHHBY is currently trading at $54.10, down $0.25 or 0.46 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.